Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers.
Lynce F, Martínez-Sáez O, Walbaum B, Brasó-Maristany F, Waks AG, Villagrasa P, Villacampa Javierre G, Sanfeliu E, Galván P, Paré L, Anderson LM, Perou CM, Parker JS, Vivancos A, DiLullo MK, Pernas S, Winer EP, Overmoyer B, Mittendorf EA, Bueno-Muiño C, Martín M, Prat A, Tolaney SM. Lynce F, et al. Among authors: galvan p. ESMO Open. 2025 Jan 17;10(2):104100. doi: 10.1016/j.esmoop.2024.104100. Online ahead of print. ESMO Open. 2025. PMID: 39826476 Free article.
Elacestrant in women with estrogen receptor-positive and HER2-negative early breast cancer: results from the preoperative window-of-opportunity ELIPSE trial.
Vidal M, Falato C, Pascual T, Sanchez-Bayona R, Muñoz-Mateu M, Cebrecos I, Gonzalez-Farré X, Cortadellas T, Margelí Vila M, Luna MA, Siso C, Amillano K, Galván P, Bergamino MA, Ferrero-Cafiero JM, Salvador F, Espinosa Guerrero A, Pare L, Sanfeliu E, Prat A, Bellet M. Vidal M, et al. Among authors: galvan p. Clin Cancer Res. 2025 Jan 16. doi: 10.1158/1078-0432.CCR-24-2460. Online ahead of print. Clin Cancer Res. 2025. PMID: 39820652
Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer.
Angelats L, Paré L, Rubio-Perez C, Sanfeliu E, González A, Seguí E, Villacampa G, Marín-Aguilera M, Pernas S, Conte B, Albarrán-Fernández V, Martínez-Sáez O, Aguirre Á, Galván P, Fernandez-Martinez A, Cobo S, Rey M, Martínez-Romero A, Walbaum B, Schettini F, Vidal M, Buckingham W, Muñoz M, Adamo B, Agrawal Y, Guedan S, Pascual T, Agudo J, Grzelak M, Borcherding N, Heyn H, Vivancos A, Parker JS, Villagrasa P, Perou CM, Prat A, Brasó-Maristany F. Angelats L, et al. Among authors: galvan p. ESMO Open. 2025 Jan 6;10(1):104109. doi: 10.1016/j.esmoop.2024.104109. Online ahead of print. ESMO Open. 2025. PMID: 39765189 Free article.
Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational study.
Schettini F, Brasó-Maristany F, Pascual T, Lorman-Carbó N, Nucera S, Bergamino M, Galván P, Conte B, Seguí E, García Fructuoso I, Gómez Bravo R, Rodríguez AB, Martínez-Sáez O, Chic N, Vidal M, Adamo B, González-Farre B, Sanfeliu E, Cebrecos I, Mensión E, Oses G, Locci M, Mollà M, Ganau S, Jares P, Vidal-Sicart S, Muñoz M, Prat A. Schettini F, et al. Among authors: galvan p. ESMO Open. 2024 Dec;9(12):103989. doi: 10.1016/j.esmoop.2024.103989. Epub 2024 Nov 27. ESMO Open. 2024. PMID: 39608304 Free PMC article.
Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy.
Pernas S, Sanfeliu E, Villacampa G, Salvador J, Perelló A, González X, Jiménez B, Merino M, Palacios P, Pascual T, Alba E, Villanueva L, Chillara S, Ferrero-Cafiero JM, Galvan P, Prat A, Ciruelos E. Pernas S, et al. Among authors: galvan p. NPJ Breast Cancer. 2024 Nov 26;10(1):101. doi: 10.1038/s41523-024-00710-x. NPJ Breast Cancer. 2024. PMID: 39592624 Free PMC article.
Multistate outbreak of Salmonella Oranienburg infections linked to bulb onions imported from Mexico - United States, 2021.
Mitchell MR Jr, Kirchner M, Schneider B, McClure M, Neil KP, Madad A, Jemaneh T, Tijerina M, Nolte K, Wellman A, Neises D, Pightling A, Swinford A, Piontkowski A, Sexton R, McKenna C, Cornell J, Sandoval AL, Wang H, Bell RL, Stager C, Nava MCZ, de la Cruz JLL, Córdova LIS, Galván PR, Ortiz JA, Flowers S, Grisamore A, Gieraltowski L, Bazaco M, Viazis S. Mitchell MR Jr, et al. Among authors: galvan pr. Food Control. 2024 Jun;160:110325. doi: 10.1016/j.foodcont.2024.110325. Food Control. 2024. PMID: 39493539
Neoadjuvant sunitinib plus exemestane in post-menopausal women with hormone receptor-positive/HER2-negative early-stage breast cancer (SUT_EXE-08): a phase I/II trial.
Fullana B, Morales S, Petit A, Alay A, Verdaguer H, Climent F, Navarro-Perez V, Cejuela M, Galvan P, Gumà A, Llombart-Cussac A, Cordero D, Casanovas O, Prat A, Gil-Gil M, Pernas S. Fullana B, et al. Among authors: galvan p. Sci Rep. 2024 Oct 9;14(1):23626. doi: 10.1038/s41598-024-72152-1. Sci Rep. 2024. PMID: 39384801 Free PMC article. Clinical Trial.
HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial.
Llombart-Cussac A, Pérez-García J, Brasó-Maristany F, Paré L, Villacampa G, Gion M, Schmid P, Colleoni M, Borrego MR, Galván P, Parker JS, Buckingham W, Perou CM, Villagrasa P, Guerrero JA, Sampayo-Cordero M, Mancino M, Prat A, Cortés J. Llombart-Cussac A, et al. Among authors: galvan p. Clin Cancer Res. 2024 Sep 13;30(18):4123-4130. doi: 10.1158/1078-0432.CCR-24-0464. Clin Cancer Res. 2024. PMID: 38995291 Free PMC article. Clinical Trial.
129 results